Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Emflaza™ (deflazacort) – New orphan drug approval
February 9, 2017 – The FDA announced the approval of Marathon’s Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.
